Cargando…

Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results

OBJECTIVES: Adjuvant chemotherapy decision in patients with hormone receptor positive, HER2 negative breast cancer (BC) is challenging. Ki-67 is widely used for adjuvant therapy decision in BC. The multigene assay EndoPredict (EP) has shown to provide valid and additional information about the risk...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noske, Aurelia, Anders, Sophie-Isabelle, Ettl, Johannes, Hapfelmeier, Alexander, Steiger, Katja, Specht, Katja, Weichert, Wilko, Kiechle, Marion, Klein, Evelyn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375593/ https://www.ncbi.nlm.nih.gov/pubmed/31786414 http://dx.doi.org/10.1016/j.breast.2019.11.004

Ejemplares similares

First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer
por: Ettl, Johannes, et al.
Publicado: (2020)

Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1
por: Ettl, Johannes, et al.
Publicado: (2017)

Concordance between Ki-67 index in invasive breast cancer and molecular signatures: EndoPredict and MammaPrint
por: Amezcua-Gálvez, Jesús Eduardo, et al.
Publicado: (2022)

Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer
por: Noske, Aurelia, et al.
Publicado: (2021)

Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer
por: Varga, Zsuzsanna, et al.
Publicado: (2013)

Correction: Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer
por: Varga, Zsuzsanna, et al.
Publicado: (2013)

The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions
por: Müller, Berit Maria, et al.
Publicado: (2013)

EndoPredict(®) in early hormone receptor-positive, HER2-negative breast cancer
por: Almstedt, K., et al.
Publicado: (2020)

Decentral gene expression analysis for ER+/Her2− breast cancer: results of a proficiency testing program for the EndoPredict assay
por: Denkert, Carsten, et al.
Publicado: (2012)

Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value
por: Chow, Louis W C, et al.
Publicado: (2017)

Individualized Chemotherapy Benefit Prediction by EndoPredict in Patients With Early Breast Cancer in an Indian Cohort
por: Somashekhar, S. P., et al.
Publicado: (2020)

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
por: Buus, Richard, et al.
Publicado: (2021)

Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes
por: Viale, Giuseppe, et al.
Publicado: (2019)

Introducing a novel highly prognostic grading scheme based on tumour budding and cell nest size for squamous cell carcinoma of the uterine cervix
por: Jesinghaus, Moritz, et al.
Publicado: (2018)

Ki-67 expression in luminal type breast cancer and its association with the clinicopathology of the cancer
por: YUAN, PENG, et al.
Publicado: (2016)

MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers
por: Sadeghian, Dorsay, et al.
Publicado: (2022)

Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study
por: Buus, Richard, et al.
Publicado: (2021)

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
por: Cheang, Maggie C. U., et al.
Publicado: (2009)

CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer
por: Seitz, Stefanie, et al.
Publicado: (2022)

Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections
por: Müller, Berit Maria, et al.
Publicado: (2012)

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
por: Dubsky, P, et al.
Publicado: (2013)

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
por: Buus, Richard, et al.
Publicado: (2016)

Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
por: Constantinidou, Anastasia, et al.
Publicado: (2022)

Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2–14)
por: Penault-Llorca, Frédérique, et al.
Publicado: (2019)

P16/Ki-67 Immunostaining is Useful in Stratification of Atypical Metaplastic Epithelium of the Cervix
por: Walts, Ann E., et al.
Publicado: (2008)

Getting deep in the luminal B breast cancer subtype and its ki67 cut-off value
por: Ciruelos, E, et al.
Publicado: (2011)

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer
por: Horimoto, Yoshiya, et al.
Publicado: (2014)

Can Histological Grade and Mitotic Index Replace Ki67 to Determine Luminal Breast Cancer Subtypes?
por: Oddó, David, et al.
Publicado: (2018)

Combined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients
por: Hao, Junmei, et al.
Publicado: (2021)

Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer
por: Pons, Laura, et al.
Publicado: (2022)

Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information
por: Inic, Zorka, et al.
Publicado: (2014)

MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer
por: Bösl, Andreas, et al.
Publicado: (2017)

Demand for integrative medicine among women in pregnancy and childbed: a German survey on patients’ needs
por: Schürger, Nikolas, et al.
Publicado: (2018)

PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma
por: Vag, Tibor, et al.
Publicado: (2018)

CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity
por: Straub, Melanie, et al.
Publicado: (2016)

Independent Tissue-Based Biomarkers in Endometrioid Endometrial Cancer: Tumor Budding in Microsatellite Instability and WHO Grading in Copy-Number-Low Patients
por: Stögbauer, Fabian, et al.
Publicado: (2023)

Ki67 assessment in invasive luminal breast cancer: a comparative study between different scoring methods
por: Lashen, Ayat, et al.
Publicado: (2022)

Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma
por: Tang, Lirui, et al.
Publicado: (2022)

Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer
por: Peláez-García, Alberto, et al.
Publicado: (2017)

Clinically high-risk breast cancer displays markedly discordant molecular risk predictions between the MammaPrint and EndoPredict tests
por: Jahn, Stephan Wenzel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_oppajhojbo81jp511o486ffn75